IP Library › Granted Patent US 12,241,077
Granted Patent B2
US 12,241,077 · App. 17/038,482 · Granted Mar 4, 2025

Adeno-associated virus (AAV) systems for treatment of genetic hearing loss

Inventors: Christopher Bartolome (Billerica, MA); Luis David Jaramillo (Cambridge, MA); Adrian M. Timmers (Burlington, MA); Steven Pennock (Leominster, MA); Mark Shearman (Alachua, FL)
Assignee: Eli Lilly and Company
C12N15/86C07H21/04C12N15/66C12N15/8645C12N2510/00C12N2710/10041
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,241,077
App. No.
17/038,482
Granted
Mar 4, 2025
Kind
B2
Abstract

Described herein are codon optimized nucleic acid sequences encoding gap junction protein beta 2 (GJB2), and associated genetic elements, for use in recombinant adeno-associated virus (rAAV)-based gene therapy. The rAAV vectors through which GJB2 is packaged can be used for targeted delivery to patients suffering from genetic hearing loss, including patients with autosomal mutations, recessive or dominant, in the GJB2 gene.

Claims (20)

1. An isolated polynucleotide comprising a nucleic acid sequence encoding a codon optimized gap junction protein beta 2 (GJB2), wherein the nucleic acid sequence is at least 85% identical to SEQ ID NO: 18.

2. The polynucleotide of claim 1 , comprising in the following order CBA-GJB2 (X)-HA-WPRE-pA, where X comprises a nucleic acid sequence at least 85% identical to SEQ ID NO: 18.

3. A host cell comprising the polynucleotide of claim 1 .

4. A recombinant herpes simplex virus (rHSV) comprising the polynucleotide of claim 1 .

5. A transgene expression cassette comprising:

the polynucleotide of claim 1 ; and

minimal regulatory elements.

6. A nucleic acid vector comprising the expression cassette of claim 5 .

7. The vector of claim 6 , wherein the vector is an adeno-associated viral (AAV) vector.

8. A host cell comprising the transgene expression cassette of claim 5 .

9. A composition comprising the host cell of claim 8 .

10. A composition comprising the transgene expression cassette of claim 5 .

11. A recombinant adeno-associated (rAAV) expression vector comprising the polynucleotide of claim 1 and an AAV genomic cassette.

12. The expression vector of claim 11 , wherein the AAV genomic cassette is flanked by two sequence-modulated inverted terminal repeats.

13. The expression vector of claim 11 further comprising a protein capsid variant optimally suited for cochlear delivery.

14. A composition comprising the rAAV expression vector of claim 11 .

15. A composition comprising the polynucleotide of claim 1 .

16. The polynucleotide of claim 1 , wherein the nucleic acid sequence encoding the codon optimized GJB2 protein is at least 95% identical to SEQ ID NO: 18.

17. The polynucleotide of claim 1 , wherein the nucleic acid sequence encoding the codon optimized GJB2 protein is at least 99% identical to SEQ ID NO: 18.

18. The polynucleotide of claim 1 , wherein the nucleic acid sequence encoding the codon optimized GJB2 protein consists of SEQ ID NO: 18.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 5, 2023
From: APPLIED GENETIC TECHNOLOGIES CORPORATION
To: OTONOMY, INC
Reel/Frame 063226/0768 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 5, 2023
From: OTONOMY, INC
To: PREVAIL THERAPEUTICS INC.
Reel/Frame 063226/0845 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 5, 2023
From: PREVAIL THERAPEUTICS INC.
To: ELI LILLY AND COMPANY
Reel/Frame 063226/0929 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2020
From: BARTOLOME, CHRIS; JARAMILLO, LUIS DAVID; TIMMERS, ADRIAN; PENNOCK, STEVEN; SHEARMAN, MARK
To: APPLIED GENETIC TECHNOLOGIES CORPORATION
Reel/Frame 054767/0116 →
Continuity (2)
Provisional Application 62907834 · Sep 30, 2019
Related Publication 20210095313A1 · Apr 1, 2021
References Cited (27)
US 20050281786A1 · Poulsen et al. · 2005 [cited by applicant]
CN 101522899A · 2009 [cited by applicant]
CN 108135991A · 2018 [cited by applicant]
CN 108350467A · 2018 [cited by applicant]
CN 109055499A · 2018 [cited by applicant]
CN 109310745A · 2019 [cited by applicant]
WO WO2007132169A1 · 2007 [cited by examiner]
WO 2015130840A2 · 2015 [cited by applicant]
WO 2017136764A1 · 2017 [cited by applicant]
WO 2017191274A2 · 2017 [cited by applicant]
WO 2022056444A1 · 2022 [cited by applicant]
Wang, B., 2012 (Geneseq Accession No. AZX45003, computer printout, pp. 1-2). [cited by examiner]
Iizuka et al., 2015 (Human Molecular Genetics, vol. 24, No. 13, p. 3651-3661). [cited by examiner]
Ill et al., 2005 (Gene Therapy, 12: 795-802). [cited by examiner]
GenBank Accession No. AY275646, [cited by applicant]
Maeda et al., In vitro and in vivo suppression of GJB2 expression by RNA interference. Hum Mol Genet. Jun. 15, 2005;14(12):1641-50. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2020/053561, dated Feb. 19, 2021, 11 pages. [cited by applicant]
Crispino et al., BAAV mediated GJB2 gene transfer restores gap junction coupling in cochlear organotypic cultures from deaf Cx26Sox10Cre mice. PLoS One. 2011;6(8):e23279, 11 pages. [cited by applicant]
GenBank Accession No. MH311557, [cited by applicant]
GenBank Accession No. NM_001004099, Rattus norvegicus gap junction protein, beta 2 (Gjb2), mRNA. 3 pages, Aug. 2, 2019. [cited by applicant]
Gyorgy et al., Gene Transfer with AAV9-PHP.B Rescues Hearing in a Mouse Model of Usher Syndrome 3A and Transduces Hair Cells in a Non-human Primate. Mol Ther Methods Clin Dev. Nov. 20, 2018;13:1-13. [cited by applicant]
Jackson et al., Better Targeting, Better Efficiency for Wide-Scale Neuronal Transduction with the Synapsin Promoter and AAV-PHP.B. Front Mol Neurosci. Nov. 4, 2016;9:116, 11 pages. [cited by applicant]
Kemperman et al., Hearing loss and connexin 26. J R Soc Med. Apr. 2002;95(4):171-7. [cited by applicant]
Lefebvre et al., Connexins, hearing and deafness: clinical aspects of mutations in the connexin 26 gene. Brain Res Brain Res Rev. Apr. 2000;32(1):159-62. [cited by applicant]
Smith et al., GJB2-Related Autosomal Recessive Nonsyndromic Hearing Loss. GeneReviews. University of Washington, Seattle, MP Adam (Ed.). 31 pages, Jul. 20, 2023. [cited by applicant]
Thomas et al., Scalable recombinant adeno-associated virus production using recombinant herpes simplex virus type 1 coinfection of suspension-adapted mammalian cells. Hum Gene Ther. Aug. 2009;20(8):861-70. [cited by applicant]
Takada et al., Connexin 26 null mice exhibit spiral ganglion degeneration that can be blocked by BDNF gene therapy. Hear Res. Mar. 2014;309:124-35. [cited by applicant]